Leerink Partnrs Predicts Beigene's Q2 Earnings (NASDAQ:ONC)

Beigene, Ltd. (NASDAQ:ONC - Free Report) - Stock analysts at Leerink Partnrs lifted their Q2 2025 earnings estimates for Beigene in a report issued on Wednesday, May 7th. Leerink Partnrs analyst A. Berens now anticipates that the company will earn ($0.08) per share for the quarter, up from their prior forecast of ($0.14). The consensus estimate for Beigene's current full-year earnings is ($5.82) per share. Leerink Partnrs also issued estimates for Beigene's Q3 2025 earnings at ($0.05) EPS, Q4 2025 earnings at ($0.04) EPS, FY2025 earnings at ($0.16) EPS and FY2027 earnings at $14.07 EPS.

Beigene (NASDAQ:ONC - Get Free Report) last issued its earnings results on Wednesday, May 7th. The company reported $1.22 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.71) by $1.93. Beigene had a negative return on equity of 25.12% and a negative net margin of 25.94%. The company had revenue of $1.12 billion for the quarter, compared to the consensus estimate of $1.12 billion.

Several other research analysts also recently commented on the stock. JMP Securities set a $348.00 price objective on shares of Beigene in a report on Friday, February 28th. TD Securities restated a "buy" rating and issued a $334.00 price target on shares of Beigene in a research report on Thursday, April 24th. Royal Bank of Canada reduced their price target on shares of Beigene from $312.00 to $311.00 and set an "outperform" rating on the stock in a research report on Thursday, May 8th. JPMorgan Chase & Co. upped their price target on shares of Beigene from $311.00 to $317.00 and gave the company an "overweight" rating in a report on Monday, April 21st. Finally, Sanford C. Bernstein set a $259.00 price target on shares of Beigene in a report on Thursday, March 13th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus target price of $319.00.

Beigene Stock Performance

Shares of ONC traded down $8.52 during midday trading on Monday, hitting $224.73. 387,726 shares of the company traded hands, compared to its average volume of 482,479. The firm has a 50 day simple moving average of $245.29. Beigene has a 52 week low of $141.31 and a 52 week high of $287.88. The stock has a market cap of $22.23 billion, a PE ratio of -27.27, a price-to-earnings-growth ratio of 7.73 and a beta of 0.35. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93.

Insider Activity at Beigene

In related news, insider Xiaodong Wang sold 41,760 shares of Beigene stock in a transaction that occurred on Monday, April 14th. The shares were sold at an average price of $242.66, for a total value of $10,133,481.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, COO Xiaobin Wu sold 51,921 shares of the company's stock in a transaction that occurred on Tuesday, April 1st. The shares were sold at an average price of $281.40, for a total transaction of $14,610,569.40. The disclosure for this sale can be found here. Insiders sold 1,146,048 shares of company stock valued at $295,198,300 over the last 90 days. Insiders own 6.62% of the company's stock.

About Beigene

BeiGene Ltd. Is a global oncology company, which engages in providing pharmaceutical products. Its medicines include BRUKINSA, TEVIMBRA, and PARTRUVIX. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in George Town, KY.